ATE367447T1 - Lentivirale verpackungszellen - Google Patents

Lentivirale verpackungszellen

Info

Publication number
ATE367447T1
ATE367447T1 AT99923020T AT99923020T ATE367447T1 AT E367447 T1 ATE367447 T1 AT E367447T1 AT 99923020 T AT99923020 T AT 99923020T AT 99923020 T AT99923020 T AT 99923020T AT E367447 T1 ATE367447 T1 AT E367447T1
Authority
AT
Austria
Prior art keywords
cell lines
gag
pol
proteins
packaging cells
Prior art date
Application number
AT99923020T
Other languages
English (en)
Inventor
Philippe Leboulch
Karen Westerman
Original Assignee
Genetix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetix Pharmaceuticals Inc filed Critical Genetix Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE367447T1 publication Critical patent/ATE367447T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Packages (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Wrappers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99923020T 1998-05-13 1999-05-13 Lentivirale verpackungszellen ATE367447T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8528398P 1998-05-13 1998-05-13

Publications (1)

Publication Number Publication Date
ATE367447T1 true ATE367447T1 (de) 2007-08-15

Family

ID=22190591

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99923020T ATE367447T1 (de) 1998-05-13 1999-05-13 Lentivirale verpackungszellen

Country Status (11)

Country Link
US (4) US6365150B1 (de)
EP (1) EP1076715B1 (de)
AT (1) ATE367447T1 (de)
AU (1) AU3988799A (de)
CA (1) CA2328404C (de)
CY (1) CY1107760T1 (de)
DE (1) DE69936577T2 (de)
DK (1) DK1076715T3 (de)
ES (1) ES2291025T3 (de)
PT (1) PT1076715E (de)
WO (1) WO1999058701A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173643A1 (en) * 1995-04-14 2002-11-21 Kappes John C. Fusion protein delivery system and uses thereof
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1076715B1 (de) * 1998-05-13 2007-07-18 Genetix Pharmaceuticals Inc. Lentivirale Verpackungszellen
US6555342B1 (en) 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
US7622300B2 (en) 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
AU778698B2 (en) * 1999-04-29 2004-12-16 Miltenyi Biotec B.V. & Co. KG Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1103615A1 (de) * 1999-11-25 2001-05-30 Universite De Geneve Vektoren, die nicht-teilende Zellen immortalisieren können und Zellen, die mit diesen Vektoren immortalisiert wurden
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
WO2002083080A2 (en) * 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
WO2002087341A1 (en) * 2001-05-01 2002-11-07 Genetix Pharmaceuticals, Inc. Novel self-inactivating (sin) lentiviral vectors
WO2002100317A2 (en) * 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
CA2466947C (en) 2001-11-19 2012-05-22 Scil Technology Gmbh A homogeneously coated device having osteoinductive and osteoconductive properties
ES2260685T3 (es) * 2002-09-10 2006-11-01 Scil Technology Gmbh Implante metalico recubierto, a una concentracion de oxigeno reducida, con proteina osteoinductora.
KR100553154B1 (ko) * 2002-10-21 2006-02-22 유지창 Ｈｉｖ 뉴클레오캡시드 단백질의 동물세포 발현용 벡터 및 이의 제조방법
US8163542B2 (en) * 2003-05-19 2012-04-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Potent combinations of mRNA transport elements
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
US8728458B2 (en) 2009-04-30 2014-05-20 The Regents Of The University Of California Combination anti-HIV vectors, targeting vectors, and methods of use
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
WO2014026053A1 (en) 2012-08-09 2014-02-13 The Regents Of The University Of California Cd25 pre-selective combination anti-hiv vectors, targeting vectors, and methods of use
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
WO2015069469A1 (en) * 2013-11-05 2015-05-14 Clontech Laboratories, Inc. Dry transfection compositions and methods for making and using the same
AU2015249381B2 (en) 2014-04-25 2020-04-30 Children's Medical Center Corporation Compositions and methods to treating hemoglobinopathies
HK1258353A1 (zh) 2016-02-23 2019-11-08 Immune Design Corp. 多基因组逆转录病毒载体制剂及用於制备及使用该制剂的方法和系统
EP3276006A1 (de) * 2016-07-27 2018-01-31 Theravectys Lentivirale vektoren zur expression von hepatitis-b-virus (hbv)-antigenen
US12350284B2 (en) 2018-05-02 2025-07-08 The Children's Medical Center Corporation BCL11A microRNAs for treating hemoglobinopathies
EP3841212A1 (de) 2018-08-24 2021-06-30 CSL Behring Gene Therapy, Inc. Vektorproduktion in serumfreien medien
US20230193255A1 (en) * 2018-11-16 2023-06-22 The Regents Of The University Of California Compositions and methods for delivering crispr/cas effector polypeptides
US11912986B2 (en) 2019-09-23 2024-02-27 The Regents Of The University Of California Methods for screening genetic perturbations
EP4277933A4 (de) 2021-01-14 2024-12-11 Senti Biosciences, Inc. Sekretierbare nutzlastregulierung
CN113186353A (zh) * 2021-05-28 2021-07-30 杭州晶佰生物技术有限公司 针对c型逆转录病毒的数字pcr检测用引物及检测方法
WO2022261150A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
DE69637677D1 (de) 1995-04-14 2008-10-23 Univ Alabama Res Found Transfer system basierend auf einem fusionsprotein und seine anwendungen.
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2237000A1 (en) 1995-11-08 1997-05-15 The Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
JP2001501815A (ja) * 1996-09-17 2001-02-13 ザ ソールク インスチチュート フォア バイオロジカル スタディズ 非分裂細胞への形質導入が可能なレトロウイルスベクター
US5908773A (en) 1996-09-20 1999-06-01 Cornell Research Foundation, Inc. KSHV positive cell lines
GB9621679D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Improved retroviral vectors
CZ137399A3 (cs) * 1996-10-17 1999-07-14 Oxford Biomedica (Uk) Limited Retrovirový produkční systém pro produkci replikačně defektivních vektorovýh partikulí
EP1076715B1 (de) * 1998-05-13 2007-07-18 Genetix Pharmaceuticals Inc. Lentivirale Verpackungszellen

Also Published As

Publication number Publication date
ES2291025T3 (es) 2008-02-16
US7311907B2 (en) 2007-12-25
WO1999058701A1 (en) 1999-11-18
US20050170507A1 (en) 2005-08-04
US20020168346A1 (en) 2002-11-14
CA2328404C (en) 2007-07-24
US6955919B2 (en) 2005-10-18
US6365150B1 (en) 2002-04-02
DE69936577D1 (de) 2007-08-30
PT1076715E (pt) 2007-10-26
DK1076715T3 (da) 2007-11-19
CA2328404A1 (en) 1999-11-18
CY1107760T1 (el) 2013-06-19
EP1076715A1 (de) 2001-02-21
US20080187997A1 (en) 2008-08-07
DE69936577T2 (de) 2008-04-30
US8034620B2 (en) 2011-10-11
AU3988799A (en) 1999-11-29
EP1076715B1 (de) 2007-07-18

Similar Documents

Publication Publication Date Title
ATE367447T1 (de) Lentivirale verpackungszellen
Nisole et al. Early steps of retrovirus replicative cycle
Wagner et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors
US6669936B2 (en) Retroviral vectors
Maurer et al. Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretrovirus
US5886166A (en) Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector
Cherepanov et al. High‐level expression of active HIV‐1 integrase from a synthetic gene in human cells
US20090291491A1 (en) Retroviral vectors
DE69435316D1 (de) Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren
ATE211766T1 (de) Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten
CA2298892A1 (en) Lentiviral vectors derived from sivagm, methods for their preparation and their use for gene transfer into mammalian cells
Negre et al. Lentiviral vectors derived from simian immunodeficiency virus
EP0816487A4 (de) Zelle, die rekombinanten hiv produziert
CA2849652C (en) Use of non-subtype b gag proteins for lentiviral packaging
Nègre et al. Vectors derived from simian immunodeficiency virus (SIV)
Pfeiffer et al. Effects of signal peptide exchange on HIV-1 glycoprotein expression and viral infectivity in mammalian cells
RU2006123079A (ru) Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы
Spirin et al. Lentiviral vectors
Von Gegerfelt et al. Replacement of posttranscriptional regulation in SIVmac239 generated a Rev-independent infectious virus able to propagate in rhesus peripheral blood mononuclear cells
DK190990A (da) Gener og deres kodede proteiner, som regulerer genekspression af interleukin-2-receptoren og af human, lymfotrope retrovira
Gopinath et al. Retroviral vectors in gene therapy
Ogata et al. Integrase of human endogenous retrovirus K-10 supports the replication of replication-incompetent Int-human immunodeficiency virus type 1 mutant
Buchow et al. HIV-I replication requires an intact integrase reading frame
Dropulic Novel lentiviral vectors for human gene therapy
Wong-Staal¹ Molecular Studies of Human T Cell Leukemia/Lymphotropic

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1076715

Country of ref document: EP

REN Ceased due to non-payment of the annual fee